Clinical Analysis Of Thalidomide With Vad Therapy For Multiple Myeloma

OBJECTIVE:To analyse the efficacy and safety of Thalidomide combined with VAD chemotherapy for multiple myeloma.METHODS:35 newly diagnosed cases were enrolled in a group of Thalidomide was given to those patients at the starting dose of 100 mg/d and added the dose until the maximum of 300 mg/d,Vindesinelmg/d on days 1～4,Epirubicin 10mg/d on days 1～4 and Dexamethasone 45mg/d on days 1～4,with 4 days as acycle.30 patients treated with VAD entered into a control group.Record gender,age,and the bone marrow before treatment, Monitoring M protein,urine light chain protein,serumβ₂-microglobulin, blood and erythrocyte sedimentation rate before and after treatment, Learning blood glucose,calcium,liver,kidney function,plasma protein,c-reactive protein changes in time,reviewwing the bone marrow after treatment at Section 4.RESULTS:With 35 cases of thalidomide United VAD,The response rate[(CR+PR)]was 80%for Thal+VAD(28 cases),specificcly,CR22.8%(8 Example),PR57.2%(20 cases),MR14.3%(5 Example),NR5.7%(2 cases). 30 cases with VAD,The response rate was43.3%(13 cases), specificcly,CR6.7%(2 cases),PR36.6%(11 cases),MR30.0%(9 cases), NR13.3%(8 cases).Compared with the two groups,The response rate in the group of Thalidomide combined with VAD chemotherapy was higher than that in the group of VAD(χ2 =0.404,p＜0.05).in a group of VAD hair loss incidence was 46.7%(14 cases),66.7%(20 cases) of patients feel abdominal distension,46.7%(14 cases) patients have mild nausea and vomiting,20%(6 cases) patients Infected with the pneumonia,the infection control though the application of antibiotic therapy,Added with thalidomide,fingers numb incidence was31.4%(11 cases), constipation 60%(21 cases),drowsiness 57.1%(20 cases),skin rash 8.6% (3 cases). CONCLUSION:Thalidomide combined with VAD chemotherapy is an effective and safe induction regimen for the newly diagnosed multiple myeloma patients and appears significantly superior to VAD,yielding high response rates in patients.